Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Corroborated by 2 sources from 2 publishers
TL;DR
Nautilus Biotechnology (NASDAQ:NAUT) reported first-quarter 2026 results and highlighted progress toward its planned commercialization timeline, with management emphasizing expanding early customer engagement, advancing its assay portfolio, and maintaining what it described as a cash runway through 2027. Invest in Gold Commercial build-out and early access momentum Co-founder and CEO Sujal Patel said the company continues to execute on milestones it outlined previously for 2026, including expanding the Iterative Mapping Early Access Program (EAP) and preparing for a commercial launch targeted for late 2026. Patel reiterated prior expectations that Nautilus plans to open the Voyager Platform for pre-orders in late 2026, with customer installations beginning in early 2027 and general availability of broad-scale capabilities in the first half of 2027.